Among patients with inflammatory bowel disease who received at least two biologic therapies, discontinuation of treatment appeared to vary based on initial treatment choice, according to data presented at the ACG Annual Scientific Meeting.

“Decisions about choice of biologic for treatment of moderate to severe Crohn’s disease and ulcerative colitis are complex, owing to limited data on the comparative effectiveness of treatments,” Noa Krugliak Cleveland, MD, gastroenterology and advanced IBD fellow at the University of Chicago Medicine, said during a virtual poster

Full Article: